Roivant Sciences (ROIV) Non-Current Assets (2021 - 2026)
Roivant Sciences (ROIV) reported Non-Current Assets of $153000.0 for Q1 2026, down 24.26% on a YoY basis from $202000.0 in Q1 2025, and down 100.0% quarter-over-quarter from $4.3 billion in Q4 2025.
Roivant Sciences (ROIV) Non-Current Assets (2021 - 2026) Analysis & Trends
Roivant Sciences has reported Non-Current Assets for 6 years, with the latest figure at $153000.0 in Q1 2026.
- For the quarter ending Q1 2026, Non-Current Assets fell 24.26% year-over-year to $153000.0; the trailing twelve-month figure through Mar 2026 stood at $153000.0 (down 24.26% YoY), and the FY2026 full-year result was $153000.0, down 24.26% from the prior year.
- Non-Current Assets for Q1 2026 stood at $153000.0, down from $4.3 billion in the prior quarter.
- The five-year high for Non-Current Assets was $4.3 billion in Q4 2025, with the low at $153000.0 in Q1 2026.
- Historically, Non-Current Assets has averaged $837.3 million across 5 years, with a median of $513.9 million in 2023.
- Annual changes were most pronounced in 2023 — Non-Current Assets soared 257.11% — and 2025, when it sank 98.6%.
- Roivant Sciences' Non-Current Assets stood at $556.7 million in 2022, then soared by 257.11% to $2.0 billion in 2023, then increased by 17.73% to $2.3 billion in 2024, then surged by 83.05% to $4.3 billion in 2025, then plunged by 100.0% to $153000.0 in 2026.
- The last three Non-Current Assets figures came in at $153000.0 (Q1 2026), $4.3 billion (Q4 2025), and $551.0 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 62,953.78 |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 289.41 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 4.56 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 486.60 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 30.30 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 5.18 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 14.75 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 39.71 Mn |
| 10 | Roivant Sciences | 21.82 Bn | 22.59 Bn | - | 153,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 153,000.00 |
| Dec 31, 2025 | 4.28 Bn |
| Sep 30, 2025 | 550.95 Mn |
| Jun 30, 2025 | 416.85 Mn |
| Mar 31, 2025 | 202,000.00 |
| Dec 31, 2024 | 2.34 Bn |
| Sep 30, 2024 | 404.91 Mn |
| Jun 30, 2024 | 494.95 Mn |
| Mar 31, 2024 | 14.42 Mn |
| Dec 31, 2023 | 1.99 Bn |
| Sep 30, 2023 | 513.92 Mn |
| Jun 30, 2023 | 575.49 Mn |
| Mar 31, 2023 | 591.02 Mn |
| Dec 31, 2022 | 556.73 Mn |
| Sep 30, 2022 | 500.67 Mn |
| Jun 30, 2022 | 560.96 Mn |
| Mar 31, 2022 | 438.61 Mn |
| Dec 31, 2021 | 511.84 Mn |
| Sep 30, 2021 | 547.15 Mn |
| Jun 30, 2021 | 397.09 Mn |